Trials / Not Yet Recruiting
Not Yet RecruitingNCT07407010
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
A Prospective Single-Arm, Single-Center Study of BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in Relapsed or Refractory Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of BCMA/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM336 (BCMA/CD3 bispecific antibody) | CM336 is a BCMA × CD3 bispecific antibody. |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2027-05-31
- Completion
- 2028-05-31
- First posted
- 2026-02-12
- Last updated
- 2026-02-12
Source: ClinicalTrials.gov record NCT07407010. Inclusion in this directory is not an endorsement.